Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Making Good on Biologics Investments

publication date: Dec 29, 2014
With the end of 2014 almost here, WuXi PharmaTech sent a Christmas greeting that highlights the China CRO/CMO's accomplishments in biologics, including having built the largest biologics development team of any CRO/CMO. Several years ago, WuXi identified biologics as a major focus for growth, allocating much of its considerable annual capex budget on biologics. As Chris Chen, PhD, Senior Vice President and Chief Technology Officer of WuXi, pointed out in his Christmas email, WuXi has achieved significant biologics milestones as a result. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital